PT  - JOURNAL ARTICLE
AU  - Tsvetanov, Kamen A
AU  - Spindler, Lennart R B
AU  - Stamatakis, Emmanuel A
AU  - Newcombe, Virginia FJ
AU  - Lupson, Victoria C
AU  - Chatfield, Doris A
AU  - Manktelow, Anne E
AU  - Outtrim, Joanne G
AU  - Elmer, Anne
AU  - Kingston, Nathalie
AU  - Bradley, John R
AU  - Bullmore, Edward T
AU  - Rowe, James B
AU  - Menon, David K
AU  - ,
AU  - ,
AU  - ,
AU  - ,
TI  - Hospitalisation for COVID-19 predicts long lasting cerebrovascular impairment: A prospective observational cohort study
AID  - 10.1101/2022.02.01.22270235
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.02.01.22270235
4099  - http://medrxiv.org/content/early/2022/02/02/2022.02.01.22270235.short
4100  - http://medrxiv.org/content/early/2022/02/02/2022.02.01.22270235.full
AB  - Human coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has multiple neurological consequences, but its long-term effect on brain health is still uncertain. The cerebrovascular consequences of COVID-19 may also affect brain health. Here we assess cerebrovascular health in 45 hospitalised patients using the resting state fluctuation amplitudes (RSFA) from functional magnetic resonance imaging, in relation to disease severity and in contrast with 42 controls. Widespread changes in frontoparietal RSFA were related to the severity of the acute COVID-19 episode, as indexed by COVID-19 WHO Progression Scale, inflammatory and coagulatory biomarkers. This relationship was not explained by chronic cardiorespiratory dysfunction, age, or sex. Exploratory analysis suggests that the level of cerebrovascular dysfunction is associated with cognitive, mental, and physical health at follow-up. The principal findings were consistent across univariate and multivariate approaches. The results indicate chronic cerebrovascular impairment following severe acute COVID-19, with the potential for long-term consequences on cognitive function and mental wellbeing.Competing Interest StatementAll authors have no conflicts of interest. Untreated to this there are several disclosures. VFJN holds a grant from Roche Pharmaceuticals on proteomic biomarkers in traumatic brain injury and reports personal fees from Neurodiem. ETB serves on the scientific advisory board of Sosei Hepatares and as a consultant for GSK. JBR serves as an associate editor to Brain and is a non-remunerated trustee of the Guarantors of Brain, Darwin College and the PSP Association (UK). He provides consultancy to Asceneuron, Biogen, UCB and has research grants from AZ-Medimmune, Janssen, and Lilly as industry partners in the Dementias Platform UK. DKM reports grants, personal fees, and nonfinancial support from GlaxoSmithKline Ltd.; grants, personal fees, and other from NeuroTrauma Sciences; grants and personal fees from Integra Life Sciences; personal fees from Pfizer Ltd.; grants and personal fees from Lantmannen AB; from Calico Ltd.; personal fees from Pressura Neuro Ltd.; and others from Cortirio Ltd., outside the submitted work. Funding StatementThis research was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014), NIHR funding to the NIHR BioResource (RG94028 & RG85445), Guarantors of Brain (G101149), Wellcome Trust (220258), Medical Research Council (SUAG/051G101400; and SUAG/010 RG91365), and by the Addenbrookes Charitable Trust. We thank NIHR BioResource volunteers for their participation, and gratefully acknowledge NIHR BioResource centres, NHS Trusts and staff for their contribution. We thank the National Institute for Health Research, NHS Blood and Transplant, and Health Data Research UK as part of the Digital Innovation Hub Programme. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Patients were recruited through the NIHR COVID-19 BioResource, which received ethical approval from East of England - Cambridge Central Research Ethics Committee (REC 17/EE/0025), and provided written informed consent. Eligibility was based on admission to Addenbrookes Hospital with COVID-19 between 10th March 2020 and 31st July 2020, aged 18 years or older, survived the acute illness, and attended for a follow up visit, and no contradictions to MRI. Age and sex matched controls were scanned with the same sequences, with data pooled over sequential cohorts to match demographics (Cambridgeshire Research Ethics Committee 97/290 and REC 17/EE/0025, and Norfolk EE/0395 and a protocol approved by the Human Biology Ethics Committee of the Council of the School of Biological Sciences, University of Cambridge).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode and composite data to reproduce manuscript figures, statistical analyses are available at https://github.com/kamentsvetanov/covid19_cerebrovascularburden. https://github.com/kamentsvetanov/covid19_cerebrovascularburden